Back

Colorectal cancers with distinct metastatic potential trigger divergent early T cell responses

Saad, M.; Thoms, A.; Yin, Y. S.; Mamede, I.; Rahman, A.; Chen, R.; Carrasco, S. E.; Darcy, P. W.; Goto, N.; Tavazoie, S. F.; Bilate, A. M.; Mucida, D.

2026-07-04 immunology
10.64898/2026.06.30.735606 bioRxiv
Show abstract

Colorectal cancer (CRC) remains a leading cause of cancer mortality, with most cases refractory to immunotherapy. Distinguishing tumor-induced from steady-state mucosal T cell responses has been a critical barrier to understanding antitumor immunity in CRC. Using orthotopic transplantation of CRC organoids with and without metastatic potential, combined with temporal T cell fate-mapping, we show that non-metastatic tumors elicit early recruitment of CD8{beta}+ and CD4+ T cells that acquired cytotoxic and Th1-like programs, whereas pro-metastatic tumors induce a naive-like, hypoactivated state. Tumor-infiltrating CD4+ T cells underwent clonal expansion, including clones recognizing microbial and dietary antigens. T cells in physical contact with tumor cells, identified by uLIPSTIC, were enriched for expanded and cytotoxic clones. Fate-mapped T cells from non-metastatic tumors suppressed tumor growth in an IFN-{gamma}-dependent manner, whereas pro-metastatic tumor-derived T cells failed to do so. Mechanistically, pro-metastatic tumors downregulated MHCII, and Ciita targeting in non-metastatic organoids reduced CD4+ clonal expansion and led to tumor progression. Together, these findings define divergent early T cell trajectories associated with CRC metastatic potential, indicating that ineffective local immune engagement precedes metastatic dissemination.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

1
Science Immunology
88 papers in training set
Top 0.1%
17.8%
2
Immunity
67 papers in training set
Top 0.2%
7.0%
3
Cell Reports
1498 papers in training set
Top 4%
7.0%
4
Journal for ImmunoTherapy of Cancer
75 papers in training set
Top 0.4%
6.5%
5
Nature Communications
5641 papers in training set
Top 25%
6.5%
6
Cancer Cell
42 papers in training set
Top 0.2%
6.0%
50% of probability mass above
7
Cancer Immunology Research
35 papers in training set
Top 0.2%
4.2%
8
eLife
5828 papers in training set
Top 36%
3.1%
9
Cell
431 papers in training set
Top 3%
3.1%
10
Nature
645 papers in training set
Top 5%
3.1%
11
Journal of Experimental Medicine
119 papers in training set
Top 0.9%
3.1%
12
Nature Immunology
79 papers in training set
Top 1.0%
2.5%
13
Science Signaling
65 papers in training set
Top 0.5%
2.3%
14
JCI Insight
277 papers in training set
Top 4%
2.0%
15
Gastroenterology
42 papers in training set
Top 0.5%
2.0%
16
Proceedings of the National Academy of Sciences
2444 papers in training set
Top 26%
1.8%
17
Journal of Clinical Investigation
179 papers in training set
Top 3%
1.8%
18
Gut
40 papers in training set
Top 0.6%
1.6%
19
Cancer Research
130 papers in training set
Top 2%
1.3%
20
Cell Reports Medicine
153 papers in training set
Top 4%
1.1%
21
Science Advances
1243 papers in training set
Top 27%
1.0%
22
EMBO Reports
263 papers in training set
Top 8%
0.8%
23
Frontiers in Immunology
638 papers in training set
Top 10%
0.8%
24
Cancer Discovery
66 papers in training set
Top 2%
0.8%
25
Science Translational Medicine
127 papers in training set
Top 4%
0.8%
26
OncoImmunology
24 papers in training set
Top 0.8%
0.6%
27
Cancer Letters
35 papers in training set
Top 1%
0.6%